Guanhao Biotech of Guangzhou will pay $3.1 million to acquire a 31% stake in ZY Therapeutics, a North Carolina company. ZY Therapeutics is focused on nanotech drug delivery. The company, which is developing a lyophilized cancer drug, is based on the premise that many drugs do not achieve their full therapeutic potential because they lack a controllable, targeted delivery. Guanhao is a regenerative medicine company that produces animal-sourced dura patches that is is now expanding into drug development.
Source: China Biotoday
